A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use

Table 2 ABCD scores at inclusion visit and at each monitoring visit – Quality of life population

	Inclusion visit	Monitoring visit 2 months	Monitoring visit 12–18 months
	N=197	N=191	N=97
Lipodystrophy score	3.31 (1.14)	2.23 (1.72)*	2.14 (1.61)*
Overall satisfaction with body image	2.56 (0.91)	3.30 (1.03)*	3.13 (1.01)*
Dimension A: Control and adjustment to illness, satisfaction with body image	53.13 (21.24)	67.84 (23.73)*	66.19 (20.04)*
Dimension B: Psychological, social and relational impact	52.13 (22.85)	67.37 (22.84)*	65.08 (18.62)*
Dimension C: Fear of the future	60.00 (24.04)	70.53 (24.08)*	65.08 (18.62) ^†
Dimension D: Impact of treatment	83.74 (21.09)	87.63 (19.74)*	86.60 (19.87) ^†
Overall ABCD quality of life score	56.55 (18.97)	69.93 (20.53)*	67.92 (16.91)*

* Comparison with score at inclusion: Wilcoxon Test, p = <0.001.
† Comparison with score at inclusion: Wilcoxon Test, p = <0.05.
Means provided with standard error of measurement (SEM) in parentheses.
Scores for Dimensions A to D are t-transformed where 0 = worst and 100 = best possible QoL.

ISSN: 1471-2334